Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248421605> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4248421605 endingPage "1296" @default.
- W4248421605 startingPage "1296" @default.
- W4248421605 abstract "Recently, a short-course treatment using 60 daily doses of rifampin and pyrazinamide was recommended for latent tuberculosis (TB) infection (LTBI).To determine the acceptability, tolerability, and completion of treatment.Observational cohort study.Five county jails and TB outreach clinics for homeless populations in three cities.Study staff enrolled 1,211 patients (844 inmates and 367 homeless persons).Sites used 60 daily doses of rifampin and pyrazinamide, an approved treatment regimen for LTBI.Types and frequency of drug-related adverse events and outcomes of treatment.Prior to treatment, 25 of 1,178 patients (2.1%) had a serum aminotransferase measurement at least 2.5 times the upper limit of normal. Patients who reported excess alcohol use in the past 12 months were more likely than other patients to have an elevated pretreatment serum aminotransferase level (odds ratio, 2.1; 95% confidence interval, 1.1 to 6.1; p = 0.03). Treatment was stopped in 66 of 162 patients (13.4%) who had a drug-related adverse event. Among 715 patients who had serum aminotransferase measured during treatment, 43 patients (6.0%) had an elevation > 5 times the upper limits of normal, including one patient who died of liver failure attributed to treatment. In multivariate analyses, increasing age, an abnormal baseline aspartate aminotransferase level, and unemployment within the past 24 months were independent risk factors for hepatotoxicity. Completion rates were similar in jail inmates (47.5%) and homeless persons (43.6%).This study detected the first treatment-associated fatality with the rifampin and pyrazinamide regimen, prompting surveillance that detected unacceptable levels of hepatotoxicity and retraction of recommendations for its routine use. Completion rates for LTBI treatment using a short-course regimen exceeds historical rates using isoniazid. Efforts to identify an effective short-course treatment for LTBI should be given a high priority." @default.
- W4248421605 created "2022-05-12" @default.
- W4248421605 creator A5080515834 @default.
- W4248421605 date "2005-04-01" @default.
- W4248421605 modified "2023-09-24" @default.
- W4248421605 title "Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons<xref rid=AFF1><sup>*</sup></xref>" @default.
- W4248421605 doi "https://doi.org/10.1378/chest.127.4.1296" @default.
- W4248421605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15821208" @default.
- W4248421605 hasPublicationYear "2005" @default.
- W4248421605 type Work @default.
- W4248421605 citedByCount "18" @default.
- W4248421605 countsByYear W42484216052012 @default.
- W4248421605 countsByYear W42484216052013 @default.
- W4248421605 countsByYear W42484216052016 @default.
- W4248421605 countsByYear W42484216052017 @default.
- W4248421605 countsByYear W42484216052019 @default.
- W4248421605 countsByYear W42484216052021 @default.
- W4248421605 crossrefType "journal-article" @default.
- W4248421605 hasAuthorship W4248421605A5080515834 @default.
- W4248421605 hasConcept C126322002 @default.
- W4248421605 hasConcept C142724271 @default.
- W4248421605 hasConcept C156957248 @default.
- W4248421605 hasConcept C197934379 @default.
- W4248421605 hasConcept C2778375690 @default.
- W4248421605 hasConcept C2778607973 @default.
- W4248421605 hasConcept C2780459521 @default.
- W4248421605 hasConcept C2781069245 @default.
- W4248421605 hasConcept C2781413609 @default.
- W4248421605 hasConcept C44249647 @default.
- W4248421605 hasConcept C71924100 @default.
- W4248421605 hasConceptScore W4248421605C126322002 @default.
- W4248421605 hasConceptScore W4248421605C142724271 @default.
- W4248421605 hasConceptScore W4248421605C156957248 @default.
- W4248421605 hasConceptScore W4248421605C197934379 @default.
- W4248421605 hasConceptScore W4248421605C2778375690 @default.
- W4248421605 hasConceptScore W4248421605C2778607973 @default.
- W4248421605 hasConceptScore W4248421605C2780459521 @default.
- W4248421605 hasConceptScore W4248421605C2781069245 @default.
- W4248421605 hasConceptScore W4248421605C2781413609 @default.
- W4248421605 hasConceptScore W4248421605C44249647 @default.
- W4248421605 hasConceptScore W4248421605C71924100 @default.
- W4248421605 hasIssue "4" @default.
- W4248421605 hasLocation W42484216051 @default.
- W4248421605 hasLocation W42484216052 @default.
- W4248421605 hasOpenAccess W4248421605 @default.
- W4248421605 hasPrimaryLocation W42484216051 @default.
- W4248421605 hasRelatedWork W164057601 @default.
- W4248421605 hasRelatedWork W2059173653 @default.
- W4248421605 hasRelatedWork W2069472690 @default.
- W4248421605 hasRelatedWork W2380824164 @default.
- W4248421605 hasRelatedWork W2413049982 @default.
- W4248421605 hasRelatedWork W2415538921 @default.
- W4248421605 hasRelatedWork W2807439384 @default.
- W4248421605 hasRelatedWork W3202441042 @default.
- W4248421605 hasRelatedWork W4237219137 @default.
- W4248421605 hasRelatedWork W4252006871 @default.
- W4248421605 hasVolume "127" @default.
- W4248421605 isParatext "false" @default.
- W4248421605 isRetracted "false" @default.
- W4248421605 workType "article" @default.